(19)
(11) EP 3 333 181 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
24.02.2021 Bulletin 2021/08

(45) Mention of the grant of the patent:
16.12.2020 Bulletin 2020/51

(21) Application number: 18151074.4

(22) Date of filing: 14.03.2013
(51) International Patent Classification (IPC): 
C07K 14/46(2006.01)
C12N 5/10(2006.01)
C12N 15/63(2006.01)
A61P 35/00(2006.01)
C07K 14/82(2006.01)
C12N 15/12(2006.01)
A61K 38/17(2006.01)

(54)

ANTI-TUMOR PROPERTIES OF DICKKOPF 3B

ANTITUMOREIGENSCHAFTEN VON DICKKOPF 3B

PROPRIÉTÉS ANTI-TUMORALES DE DICKKOPF 3B


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 26.03.2012 US 201261615514 P

(43) Date of publication of application:
13.06.2018 Bulletin 2018/24

(62) Application number of the earlier application in accordance with Art. 76 EPC:
13768391.8 / 2831103

(73) Proprietor: University of Massachusetts
Boston, MA 02108 (US)

(72) Inventors:
  • LEONARD, Jack L.
    Shrewsbury, MA 01545 (US)
  • LEONARD, Deborah M.
    Shrewsbury, MA 01545 (US)
  • SIMIN, Karl J.
    Princeton, MA 01541 (US)

(74) Representative: Forresters IP LLP 
Skygarden Erika-Mann-Straße 11
80636 München
80636 München (DE)


(56) References cited: : 
   
  • ABARZUA F ET AL: "An N-terminal 78 amino acid truncation of REIC/Dkk-3 effectively induces apoptosis", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 375, no. 4, 31 October 2008 (2008-10-31), pages 614-618, XP025428462, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2008.08.079 [retrieved on 2008-08-24]
  • DATABASE UniProt [Online] 2 September 2008 (2008-09-02), "SubName: Full=cDNA FLJ35660 fis, clone SPLEN2017538, highly similar to Dickkopf-related protein 3 {ECO:0000313|EMBL:BAG52632.1};", XP002742843, retrieved from EBI accession no. UNIPROT:B3KS70 Database accession no. B3KS70
  • I. DEL BARCO BARRANTES ET AL: "Generation and Characterization of dickkopf3 Mutant Mice", MOLECULAR AND CELLULAR BIOLOGY, vol. 26, no. 6, 15 March 2006 (2006-03-15) , pages 2317-2326, XP055205281, ISSN: 0270-7306, DOI: 10.1128/MCB.26.6.2317-2326.2006
  • JÃ 1/4 RGEN VEECK ET AL: "Targeting the Wnt pathway in cancer: The emerging role of Dickkopf-3", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1825, no. 1, 16 September 2011 (2011-09-16), pages 18-28, XP028394058, ISSN: 0304-419X, DOI: 10.1016/J.BBCAN.2011.09.003 [retrieved on 2011-09-22]
  • JACK L. LEONARD ET AL: "The Dkk3 gene encodes a vital intracellular regulator of cell proliferation", PLOS ONE, vol. 12, no. 7, 24 July 2017 (2017-07-24), page e0181724, XP055454061, DOI: 10.1371/journal.pone.0181724
  • NAGAHARA H ET AL: "Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration", NATURE MEDICINE, NATURE PUB. CO, vol. 4, no. 12, 1 December 1998 (1998-12-01), pages 1449-1452, XP002286528, ISSN: 1078-8956, DOI: 10.1038/4042
  • D. M. LEONARD ET AL: "Cloning, Expression, and Functional Characterization of the Substrate Binding Subunit of Rat Type II Iodothyronine 5'-Deiodinase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 33, 26 May 2000 (2000-05-26) , pages 25194-25201, XP055168404, ISSN: 0021-9258, DOI: 10.1074/jbc.M002036200
  • ABARZUA F ET AL: "Adenovirus-Mediated Overexpression of REIC/Dkk-3 Selectively Induces Apoptosis in Human Prostate Cancer Cells through Activation of c-jun-NH2-Kinase", CANCER RESEARCH, AACR - AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 65, no. 21, 1 November 2005 (2005-11-01), pages 9617-9622, XP002998788, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-05-0829
  • VEECK JÃ 1/4 RGEN ET AL: "Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours", BREAST CANCER RESEARCH, CURRENT MEDICINE GROUP LTD, GB, vol. 10, no. 5, 30 September 2008 (2008-09-30), page R82, XP021046861, ISSN: 1465-5411, DOI: 10.1186/BCR2151
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).